MACROGENICS, INC.

MGNX ·Healthcare, Drug Manufacturers - General, United States
Financial Statements Income Statement
Annual Quarterly

Income Statement

Line Item FY2017 FY2016 FY2015 FY2014 FY2013 FY2012 FY2011
Revenue $157.7M $91.9M $100.9M $47.8M $58.0M $63.8M $57.2M
Cost of Revenue
Gross Profit
Gross Margin
Operating Expenses
Research & Development $147.2M $122.1M $98.3M $70.2M $46.6M $45.4M $41.1M
SG&A Expense $32.7M $29.8M $22.8M $15.9M $11.1M $10.2M $10.9M
Operating Income $-22.1M $-60.0M $-20.2M $-38.3M $366.0K $8.2M $5.2M
Operating Margin -14.0% -65.3% -20.0% -80.2% 0.6% 12.9% 9.2%
Interest Expense
Pretax Income
Income Tax Expense $0 $0 $0 $0 $0 $0
Net Income $-19.6M $-58.5M $-20.1M $-38.3M $-261.0K $8.4M $6.7M
Net Margin -12.4% -63.7% -20.0% -80.2% -0.4% 13.1% 11.7%
EPS (Basic) $-0.54 $-1.69 $-0.63 $-1.40 $-0.01 $0.00 $0.00
EPS (Diluted) $-0.54 $-1.69 $-0.63 $-1.40 $-0.01 $0.00 $0.00
Shares Outstanding (Basic) 36.1M 34.7M 31.8M 27.4M 27.4M 26.0M 24.6M
Shares Outstanding (Diluted) 36.1M 34.7M 31.8M 27.4M 27.4M 26.0M 24.6M
Dividends Per Share
← Newer Page 2 of 2 Older →